MedPath

Study of Application of Transcutaneous Trigeminal Nerve Stimulation and Sound Fusion Stimulation on Tinnitus

Not Applicable
Completed
Conditions
Tinnitus
Interventions
Device: Sound Therapy
Registration Number
NCT05291078
Lead Sponsor
Nu Eyne Co., Ltd.
Brief Summary

This study aims to evaluate the efficacy of applying transcutaneous trigeminal nerve stimulation (NUEYNE-T30, NUEYNE-T100) and sound fusion stimulation on tinnitus.

Detailed Description

Duration of study period (per participant): Screening period (-7\~0 days), Intervention period (30 days) Patient needs to visit site at least 3 times (Screening, V1, V2). V1 can be done with screening visit. Tele-visit should be done on day 15.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
25
Inclusion Criteria
  • adults suffering from tinnitus
  • Participants must be 19 to 70 years of age, at the time of screening
  • Patient who suffers from tinnitus symptom more than 3 months and scores more than 18(criteria of mild) in Tinnitus Handicap Inventory (THI) examination
  • Patients with a hearing threshold of 70dB or less when calculated using the quadrant method in the pure tone audiometry
  • A person who has no physical or mental restrictions in participating in clinical trial
  • Those who voluntarily agreed to participate in clinical trials
  • A person who has no pregnancy plan and has agreed to the contraceptive plan for infertile women during the intervention period of clinical trial
Exclusion Criteria
  • A person who does not meet the inclusion criteria
  • A person who has difficulty communicating and conducting examinations.
  • The disease of the outer or middle ear or central nervous system.
  • Subjects who have difficulty conducting clinical trials due to intellectual or cognitive impairment
  • Pregnant or lactating women
  • A person who cannot understand or read ICF (illiterate or foreigner)
  • A person who received tinnitus treatment (blood circulation enhancer, tranquilizer, tinnitus masker, biofeedback etc.) within 2 weeks of baseline or plans to receive it.
  • A person who is difficult to participate in a clinical trial according to the researcher's judgment. (e.g., heart-related problems, seizure, epilepsy. Patients transplanted metal or electronic device in head & neck. Patient suffering from unknown pain. Patients who are warned not to use out clinical trial device or is prohibited from using it.)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Experimental Group BSound TherapyTinnitus patients(n=12 people)
Experimental Group ASound TherapyTinnitus patients(n=12 people)
Control GroupSound TherapyTinnitus patients(n=12 people)
Primary Outcome Measures
NameTimeMethod
Changes in Tinnitus handicap inventory(THI) scorebaseline, 4 weeks

Check the changes in Tinnitus handicap inventory(THI) score

The score on the questionnaire ranges from 0 to 100. Higher scores mean a worse outcome.

Secondary Outcome Measures
NameTimeMethod
Changes in Pittsburg Sleep Quality Index (PSQI) scorebaseline, 4 weeks

Check the changes in Pittsburg Sleep Quality Index (PSQI) score

The score on the questionnaire ranges from 0 to 21. Higher scores mean a worse outcome.

Changes in EEGbaseline, 4 weeks

Check the changes in EEG

Changes in Loudness of Tinnitogrambaseline, 4 weeks

Check the changes in Loudness of Tinnitogram

Changes in Minimal masking level of Tinnitogrambaseline, 4 weeks

Check the changes in Minimal masking level of Tinnitogram

Changes in Beck Depression Inventory(BDI) scorebaseline, 4 weeks

Check the changes in Beck Depression Inventory score

The score on the questionnaire ranges from 0 to 63. Higher scores mean a worse outcome.

Changes in Tinnitus magnitude index(TMI) scorebaseline, 4 weeks

Check the changes in Tinnitus magnitude index(TMI) score

The questionnaire consists of three questions. The score for No. 1 question ranges from 0 to 10. The score for No. 2 question ranges from 0% to 10%. The score for No. 2 question ranges from 0mm to 100mm. Higher scores mean a worse outcome.

Changes in PPGbaseline, 4 weeks

Check the changes in PPG

Changes in MOS Short-Form 36-Item Health Survey(SF-36) scorebaseline, 4 weeks

Check the changes in MOS Short-Form 36-Item Health Survey(SF-36) score

The questionnaire consists of 8 subscales. The score for each subscale ranges from 0 to 100. Higher scores mean a better outcome.

Trial Locations

Locations (1)

Department of Otorhinolaryngology, Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath